Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Effectiveness of using fewer implanted fiducial markers for prostate target alignment.

Kudchadker RJ, Lee AK, Yu ZH, Johnson JL, Zhang L, Zhang Y, Amos RA, Nakanishi H, Ochiai A, Dong L.

Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1283-9. doi: 10.1016/j.ijrobp.2009.02.033. Epub 2009 May 7.

PMID:
19427750
2.

Intraprostatic fiducials for localization of the prostate gland: monitoring intermarker distances during radiation therapy to test for marker stability.

Kupelian PA, Willoughby TR, Meeks SL, Forbes A, Wagner T, Maach M, Langen KM.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1291-6.

PMID:
16029784
3.

Evaluation of kV cone-beam ct performance for prostate IGRT: a comparison of automatic grey-value alignment to implanted fiducial-marker alignment.

Shi W, Li JG, Zlotecki RA, Yeung A, Newlin H, Palta J, Liu C, Chvetsov AV, Olivier K.

Am J Clin Oncol. 2011 Feb;34(1):16-21. doi: 10.1097/COC.0b013e3181d26b1a.

PMID:
21189455
4.

Registration accuracy and possible migration of internal fiducial gold marker implanted in prostate and liver treated with real-time tumor-tracking radiation therapy (RTRT).

Kitamura K, Shirato H, Shimizu S, Shinohara N, Harabayashi T, Shimizu T, Kodama Y, Endo H, Onimaru R, Nishioka S, Aoyama H, Tsuchiya K, Miyasaka K.

Radiother Oncol. 2002 Mar;62(3):275-81.

PMID:
12175558
5.

[Intraprostatic fiducials in stereotactic radiotherapy for prostate cancer].

Cordoba A, Pasquier D, Nickers P, Lacornerie T, Lartigau É.

Cancer Radiother. 2016 Dec;20(8):815-819. doi: 10.1016/j.canrad.2016.07.097. Epub 2016 Oct 25. French.

PMID:
27793529
6.

Initial experience with megavoltage (MV) CT guidance for daily prostate alignments.

Langen KM, Zhang Y, Andrews RD, Hurley ME, Meeks SL, Poole DO, Willoughby TR, Kupelian PA.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1517-24.

PMID:
16029814
7.

Daily online localization using implanted fiducial markers and its impact on planning target volume for carcinoma prostate.

Khosa R, Nangia S, Chufal KS, Ghosh D, Kaul R, Sharma L.

J Cancer Res Ther. 2010 Apr-Jun;6(2):172-8. doi: 10.4103/0973-1482.65244.

8.

Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging.

Schallenkamp JM, Herman MG, Kruse JJ, Pisansky TM.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):800-11.

PMID:
16199313
9.

Microscopic gold particle-based fiducial markers for proton therapy of prostate cancer.

Lim YK, Kwak J, Kim DW, Shin D, Yoon M, Park S, Kim JS, Ahn SH, Shin J, Lee SB, Park SY, Pyo HR, Kim DY, Cho KH.

Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1609-16. doi: 10.1016/j.ijrobp.2009.02.076.

PMID:
19616746
10.

Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for on-line image-guided radiotherapy of the prostate.

Moseley DJ, White EA, Wiltshire KL, Rosewall T, Sharpe MB, Siewerdsen JH, Bissonnette JP, Gospodarowicz M, Warde P, Catton CN, Jaffray DA.

Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):942-53.

11.

Fiducial markers and spacers in prostate radiotherapy: current applications.

Ng M, Brown E, Williams A, Chao M, Lawrentschuk N, Chee R.

BJU Int. 2014 Mar;113 Suppl 2:13-20. doi: 10.1111/bju.12624. Review.

12.

Feasibility of insertion/implantation of 2.0-mm-diameter gold internal fiducial markers for precise setup and real-time tumor tracking in radiotherapy.

Shirato H, Harada T, Harabayashi T, Hida K, Endo H, Kitamura K, Onimaru R, Yamazaki K, Kurauchi N, Shimizu T, Shinohara N, Matsushita M, Dosaka-Akita H, Miyasaka K.

Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):240-7.

PMID:
12694845
13.

Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy.

Schiffner DC, Gottschalk AR, Lometti M, Aubin M, Pouliot J, Speight J, Hsu IC, Shinohara K, Roach M 3rd.

Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):610-9.

PMID:
17236978
14.

MRI-alone radiation therapy planning for prostate cancer: Automatic fiducial marker detection.

Ghose S, Mitra J, Rivest-Hénault D, Fazlollahi A, Stanwell P, Pichler P, Sun J, Fripp J, Greer PB, Dowling JA.

Med Phys. 2016 May;43(5):2218. doi: 10.1118/1.4944871.

PMID:
27147334
15.

Impact of concurrent androgen deprivation on fiducial marker migration in external-beam radiation therapy for prostate cancer.

Tiberi DA, Carrier JF, Beauchemin MC, Nguyen TV, Béliveau-Nadeau D, Taussky D.

Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):e7-e12. doi: 10.1016/j.ijrobp.2012.02.016. Epub 2012 Apr 27.

PMID:
22541962
16.

Investigation of dose perturbations and the radiographic visibility of potential fiducials for proton radiation therapy of the prostate.

Huang JY, Newhauser WD, Zhu XR, Lee AK, Kudchadker RJ.

Phys Med Biol. 2011 Aug 21;56(16):5287-302. doi: 10.1088/0031-9155/56/16/014. Epub 2011 Jul 28.

17.

Comparison of prostate set-up accuracy and margins with off-line bony anatomy corrections and online implanted fiducial-based corrections.

Greer PB, Dahl K, Ebert MA, Wratten C, White M, Denham JW.

J Med Imaging Radiat Oncol. 2008 Oct;52(5):511-6. doi: 10.1111/j.1440-1673.2008.02005.x.

PMID:
19032399
18.

[Evaluation of GoldAnchorTM fiducial marker migration during the planning of radiation treatment for patients with prostate cancer].

Bodusz D, Głowacki G, Leszczyński W, Miśta W, Miszczyk L.

Przegl Lek. 2013;70(1):11-4. Polish.

PMID:
23789298
19.

Deformation of prostate and seminal vesicles relative to intraprostatic fiducial markers.

van der Wielen GJ, Mutanga TF, Incrocci L, Kirkels WJ, Vasquez Osorio EM, Hoogeman MS, Heijmen BJ, de Boer HC.

Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1604-1611.e3. doi: 10.1016/j.ijrobp.2008.07.023.

PMID:
19028284
20.

Assessment of prostatic fiducial marker introduction: patient morbidity, staff satisfaction and improved treatment field placement.

Brown S, Lehman M, Ferrari-Anderson J, Glyde A, Burmeister E, Nicol D.

J Med Imaging Radiat Oncol. 2011 Aug;55(4):417-24. doi: 10.1111/j.1754-9485.2011.02278.x.

PMID:
21843178

Supplemental Content

Support Center